Patent · US Active

Tumor vaccination involving a humoral immune response against self-proteins

US8840902B2 · kind B2 · utility

0Cited by

1References

5Claims

0Family size

Assignee

BioNTech AG · DE

Inventors

Thorsten Klamp · Mainz, DE
Ugur Sahin · Mainz, DE
Ozlem Tureci · Homburg, DE
Michael Koslowski · Mainz, DE
Thomas Hiller · Mainz, DE
Jens Schumacher · Heidelberg, DE

Key dates

Filing date	Mar 9, 2011
Grant date	Sep 23, 2014
Priority date	—
Expiry date	Mar 9, 2031

Classification

Technology area (CPC C)Chemistry; Metallurgy
CPC primaryC12N2730/10171
WIPO fieldPharmaceuticals
WIPO sectorChemistry

Abstract

The present invention relates to tumor immunotherapy, in particular to tumor vaccination, using chimeric proteins comprising all or a portion of a hepatitis B virus core antigen protein and an amino acid sequence comprising an epitope derived from the extracellular portion of a tumor-associated antigen. In particular, the present invention provides virus-like particles comprising said chimeric proteins, which are useful for eliciting a humoral immune response in a subject against the tumor-associated antigen, in particular against cells carrying said tumor-associated antigen on their surface, wherein the tumor-associated antigen is a self-protein in said subject.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.